An Increase in GABA content in Hippocampus of Albino rats exposed to chronic restraint model and treated by Quetiapine for 3 weeks
Author(s):
Sahar Mohamed Kamal Shams El Dine
Abstract:
Quetiapine is a novel antipsychotic drug. However, there is limited clinical evidence regarding prescribing patterns for quetiapine when used as maintenance treatment for bipolar disorder. Thirty-six albino rats were divided into 3 equal groups: control normal group without exposure to chronic restraint for 6 hours daily/21 days, group received DMSO 5% (v:v), as a solvent of quetiapine, with exposure to chronic restraint for 6 hours daily/21 days and group received quetiapine 10 mg/kg/day ip for 3 weeks during exposure to chronic restraint for 6 hours daily/21 days. Intraperitoneal (ip) administration of quetiapine at a dose of 10 mg/kg/day for 3 weeks significantly (p<0.05) reduces the duration of immobility recorded by the forced swimming test (FST) and significantly (p<0.05) increases the contents of GABA neurotransmitter in hippocampus homogenates. The present study adds a positive implication of quetiapine, as an antipsychotic drug, on both the immobility and the reduction of GABA content in hippocampus of albino rats exposed restraint model for 21 days.
How to cite this article:
Sahar Mohamed Kamal Shams El Dine. An Increase in GABA content in Hippocampus of Albino rats exposed to chronic restraint model and treated by Quetiapine for 3 weeks. Pharma Innovation 2015;3(12):89-93.